Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection

AIDS

Volumn 30, Issue 16, 2016, Pages 2519-2528

  Gowda, Charitha ^a,b   Brown, Todd T ^c   Compher, Charlene ^d   Forde, Kimberly A ^b   Kostman, Jay ^e   Shaw, Pamela A ^b   Tien, Phyllis C ^f,g   Re, Vincent Lo ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Philadelphia Field Initiating Group for HIV Trials   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

HIV; Low muscle mass; Multicenter AIDS Cohort Study; Sarcopenia; Viral hepatitis; Women's Interagency HIV Study

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

ADULT; ALCOHOL CONSUMPTION; ANTHROPOMETRY; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; FEMALE; HEPATITIS VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW MUSCLE MASS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MUSCLE MASS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; VIREMIA; WAIST CIRCUMFERENCE; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPLICATION; MIDDLE AGED; MUSCLE ATROPHY; PATHOLOGY; RISK FACTOR;

ADULT; ANTHROPOMETRY; COINFECTION; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MUSCULAR ATROPHY; PREVALENCE; RISK FACTORS;

EID: 84982851810     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001213     Document Type: Article

References (70)

1. Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov 2015; 14:58-74.
2. Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol 2012; 3:260.
3. Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, et al. Consensus definition of sarcopenia, cachexia and precachexia: joint document elaborated by Special Interest Groups (SIG) ''cachexia-anorexia in chronic wasting diseases'' and ''nutrition in geriatrics''. Clin Nutr 2010; 29:154-159.
4. Erlandson KM, Allshouse AA, Jankowski CM, MaWhinney S, Kohrt WM, Campbell TB. Functional impairment is associated with low bone and muscle mass among persons aging with HIV infection. J Acquir Immune Defic Syndr 2013; 63:209-215.
5. Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, Sawyer MB. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012; 10:166-173173.e1.
6. Noori N, Kopple JD, Kovesdy CP, Feroze U, Sim JJ, Murali SB, et al. Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2010; 5:2258-2268.
7. Mangili A, Murman DH, Zampini AM, Wanke CA. Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clin Infect Dis 2006; 42:836-842.
8. Scherzer R, Heymsfield SB, Lee D, Powderly WG, Tien PC, Bacchetti P, et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS 2011; 25:1405-1414.
9. Gustafson P, Gomes VF, Vieira CS, Samb B, Naucler A, Aaby P, Lisse I. Clinical predictors for death in HIV-positive and HIVnegative tuberculosis patients in Guinea-Bissau. Infection 2007; 35:69-80.
10. Oliveira I, Andersen A, Furtado A, Medina C, da Silva D, da Silva ZJ, et al. Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study. BMJ Open 2012; 2:e001587.
11. Scrimshaw NS, Taylor CE, Gordon JE. Interactions of nutrition and infection. Monogr Ser World Health Organ 1968; 57:3-329.
12. Kulstad R, Schoeller DA. The energetics of wasting diseases. Curr Opin Clin Nutr Metab Care 2007; 10:488-493.
13. Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS 2011; 6:266-271.
14. Mulligan K, Bloch AS. Energy expenditure and protein metabolism in human immunodeficiency virus infection and cancer cachexia. Semin Oncol 1998; 25 (2 Suppl 6):82-91.
15. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44 (1 Suppl):S6-S9.
16. Ismail FW, Khan RA, Kamani L, Wadalawala AA, Shah HA, Hamid SS, Jafri W. Nutritional status in patients with hepatitis C. J Coll Physicians Surg Pak 2012; 22:139-142.
17. Meng QH, Wang JH, Yu HW, Li J, Feng YM, Hou W, et al. Resting energy expenditure and substrate metabolism in Chinese patients with acute or chronic hepatitis B or liver cirrhosis. Intern Med 2010; 49:2085-2091.
18. Qin H, Li H, Xing M, Wu C, Li G, Song J. Nutritional support treatment for severe chronic hepatitis and posthepatitic cirrhosis. J Huazhong Univ Sci Technolog Med Sci 2006; 26:217-220.
19. Henkel AS, Buchman AL. Nutritional support in patients with chronic liver disease. Nat Clin Pract Gastroenterol Hepatol 2006; 3:202-209.
20. Gowda C, Compher C, Amorosa VK, Lo Re V 3rd. Association between chronic hepatitis C virus infection and low muscle mass in US adults. J Viral Hepat 2014; 21:938-943.
21. Kalman DR, Saltzman JR. Nutrition status predicts survival in cirrhosis. Nutr Rev 1996; 54:217-219.
22. Alberino F, Gatta A, Amodio P, Merkel C, Di Pascoli L, Boffo G, Caregaro L. Nutrition and survival in patients with liver cirrhosis. Nutrition 2001; 17:445-450.
23. Lo Re V 3rd, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med 2014; 160:369-379.
24. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
25. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women's Interagency HIV Study. WIHS collaborative study group. Epidemiology 1998; 9:117-125.
26. Dudley J, Jin S, Hoover D, Metz S, Thackeray R, Chmiel J. The Multicenter AIDS Cohort Study: retention after 9 1/2 years.Am J Epidemiol 1995; 142:323-330.
27. Kaslow RA, Phair JP, Friedman HB, Lyter D, Solomon RE, Dudley J, et al. Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study. Ann Intern Med 1987; 107:474-480.
28. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. MMWR Recomm Rep 1998; 47 (RR-5):43-82.
29. Liu E, Spiegelman D, Semu H, Hawkins C, Chalamilla G, Aveika A, et al. Nutritional status and mortality among HIV-infected patients receiving antiretroviral therapy in Tanzania. J Infect Dis 2011; 204:282-290.
30. Maman D, Glynn JR, Crampin AC, Kranzer K, Saul J, Jahn A, et al. Very early anthropometric changes after antiretroviral therapy predict subsequent survival, in Karonga, Malawi. Open AIDS J 2012; 6:36-44.
31. de Waal R, Cohen K, Maartens G. Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One 2013; 8:e63623.
32. Mulligan K, Tai VW, Algren H, Abrams DI, Leiser RJ, Lo JC, Schambelan M. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2001; 26:443-448.
33. Nolan D, Hammond E, James I, McKinnon E, Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003; 8:617-626.
34. Suzuki H, Asakawa A, Amitani H, Nakamura N, Inui A. Cancer cachexia-pathophysiology and management. J Gastroenterol 2013; 48:574-594.
35. Wang XH, Mitch WE. Muscle wasting from kidney failure-a model for catabolic conditions. Int J Biochem Cell Biol 2013; 45:2230-2238.
36. Workeneh BT, Mitch WE. Review of muscle wasting associated with chronic kidney disease. Am J Clin Nutr 2010; 91:1128S-1132S.
37. Johnson CL, Fulwood R, Abraham S, Bryner JD. Basic data on anthropometric measurements and angular measurements of the hip and knee joints for selected age groups 1-74 years of age. Vital Health Stat 11 1981:1-68.
38. Kawabe N, Hashimoto S, Harata M, Nitta Y,Murao M, Nakano T, et al. Assessment of nutritional status of patients with hepatitis C virus-related liver cirrhosis. Hepatol Res 2008; 38:484-490.
39. Wasserman P, Segal-Maurer S, Rubin DS. High prevalence of low skeletal muscle mass associated with male gender in midlife and older HIV-infected persons despite CD4 cell reconstitution and viral suppression. J Int Assoc Provid AIDS Care 2013; 13:145-152.
40. de Hollander EL, Bemelmans WJ, de Groot LC. Associations between changes in anthropometric measures and mortality in old age: a role for mid-upper arm circumference? J Am Med Dir Assoc 2013; 14:187-193.
41. Figueiredo FA, Dickson ER, Pasha TM, Porayko MK, Therneau TM, Malinchoc M, et al. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease. Liver Transpl 2000; 6:575-581.
42. Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity andthemetabolic syndrome. Endocrine 2006; 29:109-117.
43. Cole TJ. The secular trend in human physical growth: a biological view. Econ Hum Biol 2003; 1:161-168.
44. Ladabaum U, Mannalithara A, Myer PA, Singh G. Obesity, abdominal obesity, physical activity, and caloric intake in US adults: 1988 to 2010. Am J Med 2014; 127:717-727e712.
45. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-1325.
46. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology 2015; 61:292-302.
47. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526.
48. Newgard CD, Lewis RJ. Missing data: how to best account for what is not known. JAMA 2015; 314:940-941.
49. Rubin DB. Multiple imputation for nonresponse in surveys. New York, NY: Wiley & Sons; 1987.
50. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-1052.
51. Melchior JC, Niyongabo T, Henzel D, Durack-Bown I, Henri SC, Boulier A. Malnutrition and wasting, immunodepression, and chronic inflammation as independent predictors of survival in HIV-infected patients. Nutrition 1999; 15:865-869.
52. Kachaamy T, Bajaj JS, Heuman DM. Muscle and mortality in cirrhosis. Clin Gastroenterol Hepatol 2012; 10:100-102.
53. Felig P, Brown WV, Levine RA, Klatskin G. Glucose homeostasis in viral hepatitis. N Engl J Med 1970; 283:1436-1440.
54. Morgan MY, Marshall AW, Milsom JP, Sherlock S. Plasma amino-acid patterns in liver disease. Gut 1982; 23:362-370.
55. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 2010; 21:33-40.
56. You X, Liu F, Zhang T, Li Y, Ye L, Zhang X. Hepatitis B virus X protein upregulates oncogene Rab18 to result in the dysregulation of lipogenesis and proliferation of hepatoma cells. Carcinogenesis 2013; 34:1644-1652.
57. Brau N, Salvatore M, Rios-Bedoya CF, Fernandez-Carbia A, Paronetto F, Rodriguez-Orengo JF, Rodriguez-Torres M. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55.
58. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134:1655-1669.
59. Tuyama AC, Hong F, Saiman Y, Wang C, Ozkok D, Mosoian A, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010; 52:612-622.
60. Castera L. Steatosis, insulin resistance and fibrosis progression in chronic hepatitis C. Minerva Gastroenterol Dietol 2006; 52:125-134.
61. Cheung O, Sanyal AJ. Hepatitis C infection and nonalcoholic fatty liver disease. Clin Liver Dis 2008; 12:573-585viii-ix.
62. Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997; 1:559-568vi-vii.
63. Parikh N, Nonnemacher MR, Pirrone V, Block T, Mehta A, Wigdahl B. Substance abuse, HIV-1 and hepatitis. Curr HIV Res 2012; 10:557-571.
64. Li TK, Schenker S, Lumeng L, National Institute on Alcohol Abuse and Alcoholism, Division of Extramural Research. Alcohol and nutrition: proceedings of a workshop, September 26-27, 1977, Indianapolis, Indiana.U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Alcohol Abuse and Alcoholism; 1979.
65. Caregaro L, Alberino F, Amodio P, Merkel C, Bolognesi M, Angeli P, Gatta A. Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr 1996; 63:602-609.
66. Baum MK. Role of micronutrients in HIV-infected intravenous drug users. J Acquir Immune Defic Syndr 2000; 25 (Suppl 1):S49-S52.
67. Hendricks KM, Erzen HD, Wanke CA, Tang AM. Nutrition issues in the HIV-infected injection drug user: findings from the nutrition for healthy living cohort. J Am Coll Nutr 2010; 29:136-143.
68. Smit E, Graham NM, Tang A, Flynn C, Solomon L, Vlahov D. Dietary intake of community-based HIV-1 seropositive and seronegative injecting drug users. Nutrition 1996; 12:496-501.
69. Loguercio C, Sava E, Marmo R, del Vecchio Blanco C, Coltorti M. Malnutrition in cirrhotic patients: anthropometricmeasurements as a method of assessing nutritional status. Br J Clin Pract 1990; 44:98-101.
70. Stosovic M, Stanojevic M, Simic-Ogrizovic S, Jovanovic D, Djukanovic L. The predictive value of anthropometric parameters on mortality in haemodialysis patients. Nephrol Dial Transplant 2011; 26:1367-1374.